This final guidance describes how the FDA determines whether to approve a humanitarian device exemption application for a device that is meant to treat or diagnose populations with uncommon medical conditions.
- This final guidance supersedes “Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and Food and Drug Administration Staff, Humanitarian Device Exemptions (HDE) Regulation: Questions and Answers” issued July 8, 2010.
- This guidance provides clarity to industry and FDA staff about current review practices for the Humanitarian Device Exemption (HDE) Program.
- This guidance explains updates to the size of the patient population and the changes in review committee requirements.
No registration is required.
|
|
|
|
No hay comentarios:
Publicar un comentario